Liraglutide placebo

DRUG3 trials

Sponsors

Novo Nordisk A/S, Amsterdam UMC, location VUmc, Psychiatric Centre Rigshospitalet

Conditions

Impaired Glucose Tolerance Associated With DrugsObesityType 2 Diabetes

Phase 2

Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?

Psychiatric Centre RigshospitaletImpaired Glucose Tolerance Associated With Drugs

Start: 2013-04-30End: 2017-03-31Updated: 2016-05-05

Phase 3

Effect and safety of liraglutide 3.0 mg on weight management in children with obesity aged 6 to <12 years: 56-week, double-blind, randomised, placebo-controlled trial

Active, not recruitingCTIS2023-508504-38-00

Novo Nordisk A/SObesity

Start: 2021-03-01Target: 21Updated: 2025-06-20

Phase 4

SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

CompletedNCT01744236

Amsterdam UMC, location VUmcType 2 Diabetes

Start: 2013-04-30End: 2015-08-31Updated: 2015-12-09

Related Papers

Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes

Diabetes & Metabolism2021-01-1259 citations

Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder

JAMA Psychiatry2017-06-10210 citations

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.

2016-09-15114 citations

Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.

2016-08-3046 citations

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Diabetologia2016-04-01124 citations

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes

BMJ Open2015-11-0130 citations

Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial

BMJ Open2014-03-0119 citations